NY-DRIVEWEALTH
DriveWealth, LLC, a global fintech investment rail and pioneer in fractional investing, today announced that following its milestone year of rapid global expansion, customer growth, and product innovation, the company has been recognized for its achievements as the category leader that is redefining investing through 10 of the most prominent industry awards. Each of these lists recognize the world’s most innovative and influential businesses and include:
- Industry awards: This year, the firm was named to the CB Insights Fintech 250 for the second consecutive year, the 2022 Deloitte Technology Fast 500, the 2022 Forbes Fintech 50, the WealthTech 100, and the Benzinga 2022 Global Fintech Awards, among others. Emily Ellis, Head of People, was also recognized with an Inspiring Fintech Female Award from NYC Fintech Women.
- Product awards: DriveWealth recently partnered with Adaptive Financial Consulting to build a new proprietary order management system (OMS) to address increased demand in its retail brokerage business. This high-throughput, low-latency OMS, which leverages Aeron technology, was recognized as 2022’s Best Collaboration/Alliance Initiative by Waters Technology’s American Financial Technology Awards.
- Workplace awards: The firm was listed as a 2022 New Jersey Top Workplace. Built In also honored the firm in its Best Places To Work Awards as one of its Best Midsize Companies to Work For and Best Paying Companies in New York City for the second consecutive year.
“Our solutions are transforming the investing landscape and we’re honored to see such positive industry recognition for our work,” said Bob Cortright, Founder of DriveWealth. “DriveWealth’s significant global growth this year can be directly attributed to the flexible scalability and customization of our platform’s APIs. We look forward to remaining the primary industry choice for fintechs who are looking to empower their customers with innovative investing solutions worldwide.”
These industry accolades built upon a number of milestones that DriveWealth achieved in 2022, including:
- Grew its global footprint: DriveWealth built upon key partnerships in Europe (Bank of Georgia) and Asia Pacific (Toss Securities), in addition to launching new partnerships in underserved markets such as Africa (Chipper Cash) and Latin America (Sproutfi) to expand affordable access to investing. In addition to notable new partnerships, DriveWealth expanded its global footprint by establishing presences in Singapore, London, Dublin, Lithuania, and Brazil to support partners and retail investors globally.
- Bolstered its innovative suite of services: DriveWealth’s Fracker®, its proprietary OMS that has reinvented the retail investing experience for millions worldwide, was granted a patent by the U.S. Patent and Trademark Office. In addition to launching two wholly-owned subsidiaries, DriveDigital and DriveLiquidity, to offer cryptocurrency capabilities to partners and their retail investors, the company launched its Developer Dashboard to enable developers to gain free, instant access to the same resilient and scalable APIs that DriveWealth’s partners access in a sandbox environment. Finally, the firm expanded its DriveAdvisory platform, a technology infrastructure solution that empowers partners to fully integrate financial advisory products into their existing apps.
DriveWealth anticipates significant opportunities for growth in 2023, supported by results included in its proprietary DriveTrends report, which showed that digital trading became increasingly popular this year among global Millennials even amid 2022 market lows – a trend expected to continue into 2023. The study analyzed data from more than 12 million investors worldwide who trade fractional shares of U.S. equities through DriveWealth’s network of 100+ global partners, including MoneyLion, Revolut, Grupo Bursátil Mexicano (GBM), and Goalsetter, among others.
About DriveWealth
DriveWealth, a global fintech investment rail and pioneer of fractional equities trading, is a visionary technology company that empowers more than 100 partners around the world to engage their customers by placing the markets in the palm of their hands. We believe the future is fractional, transactional and mobile. Every mobile device should be a gateway to accessing investing and savings products, services, advice, and assistance for global citizens of all ages, wealth stages, and levels of financial expertise. DriveWealth’s consultative support and cloud-based, modern technology platform allow partners to seamlessly offer branded investing experiences to drive customer acquisition, loyalty, retention, and revenue growth. For more information, please visit drivewealth.com or connect with us on Twitter @DriveWealth or on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221222005077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom